A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome Clinical Trial

Official title:
A Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients With WHIM Syndrome

Status Completed

Clinical Trial Summary

This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in an Extension Phase, if regionally applicable, until it becomes commercially available or until the study is terminated by the Sponsor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03005327
Study type	Interventional
Source	X4 Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	December 2016
Completion date	June 16, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT03995108` - Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome	Phase 3
	Withdrawn	`NCT03087370` - A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome